Half-year report · HY
4502.TEDINET S100WX9G
Period2025-04-01 → 2025-09-30
Filed2025-10-30
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.22T | 2025-04-01 → 2025-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥4.58T | 2024-04-01 → 2025-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥2.38T | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥253.6bn | 2025-04-01 → 2025-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥350.6bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥178.8bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥175.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥256.0bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥112.4bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥107.9bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥187.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥112.5bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥108.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥187.4bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥14.47T | at 2025-09-30 | Cons. | Assets IFRS |
| Total assets | ¥14.25T | at 2025-03-31 | Cons. | Assets IFRS |
| Total assets | ¥14.57T | at 2024-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥7.34T | at 2025-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥7.31T | at 2025-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥7.13T | at 2025-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥6.94T | at 2025-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥6.92T | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥7.27T | at 2024-03-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥7.13T | at 2025-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥6.94T | at 2025-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Cash & equivalents | ¥681.5bn | at 2025-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥385.1bn | at 2025-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥859.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥457.8bn | at 2024-03-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥593.7bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥1.06T | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥451.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥81.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥367.1bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥231.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥226.9bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥751.4bn | 2024-04-01 → 2025-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥206.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥71.57 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥68.36 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥118.85 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥70.45 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥67.23 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥117.11 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 49.3% | at 2025-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 48.7% | at 2025-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 47.5% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 660
| Item | Context | Value | Unit |
|---|---|---|---|
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-10-30 | |
| Semi annual accounting period cover page | FilingDateInstant | Original text (Japanese)第149期中(自 2025年４月１日 至 2025年９月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)武田薬品工業株式会社 | |
| Company name in english cover page | FilingDateInstant | Takeda Pharmaceutical Company Limited | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長CEO クリストフ ウェバー | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)大阪府大阪市中央区道修町四丁目１番１号（上記は登記上の本店所在地で実際の業務は「最寄りの連絡場所」で行っております。） | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)該当なし | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)該当なし | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都中央区日本橋本町二丁目１番１号(武田薬品工業株式会社武田グローバル本社) | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)03(3278)2111(代表) | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)グローバルファイナンス チーフアカウンティングオフィサー＆コーポレートコントローラー 竹田 徳正 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E00919 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45020 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)武田薬品工業株式会社 | |
| Filer name in english | FilingDateInstant | Takeda Pharmaceutical Company Limited | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2025-04-01 | |
| Current period end date | FilingDateInstant | 2025-09-30 | |
| Type of current period | FilingDateInstant | HY | |
| Current fiscal year end date | FilingDateInstant | 2026-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2024-04-01 | |
| Comparative period end date | FilingDateInstant | 2024-09-30 | |
| Previous fiscal year end date | FilingDateInstant | 2025-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京（プライム市場）、名古屋（プレミア市場）、福岡、札幌、ニューヨーク各証券取引所 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数は100株であります。 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |